Antiplatelet Agents in the Perioperative Period

James M. O’Riordan, MD; Ronan J. Margey, MB; Gavin Blake, MD; P. Ronan O’Connell, MD

Objective: To determine the use of the 3 major classes of antiplatelet drugs (aspirin, thienopyridines, and glycoprotein IIb/IIIa inhibitors), their management in the perioperative period, and the risks associated with premature withdrawal.

Data Sources: We reviewed the PubMed, EMBASE, and Cochrane databases using the terms antiplatelet agents in the perioperative period, antiplatelet agents and management of bleeding, drug-eluting stents and stent thrombosis, substitutes for antiplatelet agents, and premature withdrawal of antiplatelet agents.

Study Selection: Randomized, double-blind, placebo-controlled trials; prospective observational studies; review articles; clinical registry data; and guidelines of professional bodies pertaining to antiplatelet agents were included.

Data Extraction and Synthesis: Two researchers independently read the selected abstracts and selected the studies that matched the inclusion criteria. Any discordance between the 2 researchers was resolved by discussion so that 99 articles were finally included.

Conclusions: Aspirin use should not be stopped in the perioperative period unless the risk of bleeding exceeds the thrombotic risk from withholding the drug. With the exception of recent drug-eluting stent implantation, clopidogrel bisulfate use should be stopped at least 5 days prior to most elective surgery. Use of glycoprotein IIb/IIIa inhibitors must be discontinued preoperatively for more than 12 hours to allow normal hemostasis. Premature withdrawal of antiplatelet agents is associated with a 10% risk of all vascular events. Following drug-eluting stent implantation, withdrawal is associated with stent thrombosis and potentially fatal consequences. No definitive guidelines exist to manage patients who are actively bleeding while taking these drugs.

Arch Surg. 2009;144(1):69-76

Platelets play a central role in atherosclerotic plaque disruption and subsequent thrombus formation. Understanding the processes of platelet activation and aggregation has led to the widespread use of antiplatelet therapies in cardiovascular disease.

Aspirin is the most widely prescribed antiplatelet drug. More powerful new antiplatelet agents are superior in patients with recent myocardial infarction, ischemic stroke, or symptomatic peripheral arterial disease. Coadministration of 2 antiplatelet agents, such as aspirin and clopidogrel bisulfate, enhances platelet inhibition, as each binds to a different receptor.

See Invited Critique at end of article

Advances in interventional cardiology have resulted in a growing population of patients taking antiplatelet agents following percutaneous coronary intervention (PCI). New technologies, such as drug-eluting stents (DESs) and drug-coated balloon angioplasty, have increased patency rates at 1 year and reduced the levels of neointimal hyperplasia and stent restenosis compared with balloon angioplasty alone and bare-metal stenting (BMS). Drug-eluting stents are currently used in the majority of patients undergoing PCI. Glycoprotein (Gp) IIb/IIIa inhibitors, such as ReoPro (Eli Lilly and Company, Indianapolis, Indiana, and Centocor, Horsham, Pennsylvania) (abciximab), are used as an adjunct to PCI for the prevention of cardiac ischemic complications.

Most general surgeons are familiar with warfarin as an anticoagulant and perioperative management in terms of elective heparin bridging or reversal. However, many are unfamiliar with newer antiplatelet agents, the guidelines for antiplatelet therapy following PCI and acute coronary syndrome (ACS), and the serious consequences associated with premature withdrawal of these agents. A recent audit among vascular surgeons in the United Kingdom showed wide variation in practice with no consensus with regard to thienopyridine use and major vascular surgical procedures. Similarly, Joseph et al showed a lack of consensus with regard to stopping clopidogrel use in the perioperative period among orthopedic surgeons.
The decision to stop antiplatelet medication administration in the perioperative period may be simple if the thrombotic risk is overwhelming and the bleeding risk negligible. The situation is however frequently more complex and a risk-benefit assessment must be undertaken. The aims of this article were to review the pharmacokinetics of the 3 major classes of antiplatelet drugs (aspirin, thienopyridines, and Gp IIb/IIIa inhibitors), the current indications for their use, the management of bleeding while taking these antiplatelet agents, and the consequences of premature withdrawal of antiplatelet therapy.

<table>
<thead>
<tr>
<th>Clinical Setting</th>
<th>Recommendation</th>
<th>Level of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stable CAD</td>
<td>Aspirin (75-162 mg/d)</td>
<td>1A</td>
</tr>
<tr>
<td></td>
<td>Aspirin continued indefinitely</td>
<td>2C</td>
</tr>
<tr>
<td>Stable CAD with risk profile indicating increased risk for ACS</td>
<td>Long-term clopidogrel plus aspirin</td>
<td>2C</td>
</tr>
<tr>
<td>Non-ST-segment ACS</td>
<td>Aspirin (75-162 mg/d) continued lifelong</td>
<td>1A</td>
</tr>
<tr>
<td></td>
<td>Clopidogrel (75 mg/d) for 12 mo</td>
<td>1A/1B</td>
</tr>
<tr>
<td>Stable patient after placement of BMS</td>
<td>Clopidogrel (75 mg/d) for 4 wk</td>
<td>1A</td>
</tr>
<tr>
<td>Stable patient after placement of DES</td>
<td>Clopidogrel (75 mg/d) for 12 mo</td>
<td>1C</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>Age $&lt;65$ y and without risk factors: aspirin (325 mg)</td>
<td>1B</td>
</tr>
<tr>
<td></td>
<td>Age $65-75$ y and without risk factors: aspirin or warfarin (if warfarin not indicated for CAD)</td>
<td>1A</td>
</tr>
<tr>
<td>Secondary prevention when cerebrovascular disease</td>
<td>Either aspirin (50-325 mg) or aspirin (25 mg) + controlled-release dipyridamole (200 mg twice a day) or clopidogrel (if warfarin not indicated for CAD)</td>
<td>1A</td>
</tr>
<tr>
<td>Carotid endarterectomy</td>
<td>Aspirin (75-325 mg), started preoperatively (at the expense of increased bleeding risk)</td>
<td>1A</td>
</tr>
<tr>
<td>Chronic peripheral arterial disease</td>
<td>Aspirin at a dose depending on the presence of CAD or cerebrovascular disease</td>
<td>1A</td>
</tr>
<tr>
<td>Primary prevention (coronary events)</td>
<td>Intermediate risk: aspirin (75-162 mg)</td>
<td>2A</td>
</tr>
</tbody>
</table>

Abbreviations: ACS, acute coronary syndrome; BMS, bare-metal stent; CAD, coronary artery disease; DES, drug-eluting stent.

The current uses of oral antiplatelet agents are presented in Table 1, derived from the recommendations of the American College of Chest Physicians.17

**RESULTS**

**ASPIRIN**

Aspirin or acetylsalicylic acid is the most widely prescribed antiplatelet drug since the first randomized trial showed a link between aspirin and reduced risk of myocardial infarction.19 Aspirin works by irreversibly acetylating serine 529 of cyclooxygenase (COX) 1, resulting in inhibition of thromboxane A2 release from platelets and prostacyclin from endothelial cells.20 Thromboxane A2 stimulates platelet activation, whereas prostacyclin inhibits platelet activation. Because platelets are unable to generate significant amounts of new COX, the effects of aspirin-induced COX-1 inhibition last for the lifetime of the platelet. In contrast, endothelial cells recover normal function shortly after exposure to aspirin; therefore, aspirin is an antithrombotic agent.

The benefits of aspirin were first recognized in the ISIS-2 trial.21 In high-risk patients, aspirin reduced the risk of a serious thrombotic event by approximately 25%. However, 10% to 20% of patients treated with aspirin following an arterial thrombotic event subsequently have a further arterial thrombotic event.22,23 Aspirin alone is not sufficient to prevent stent thrombosis in the initial phase poststenting. This prompted development of adjunctive antithrombotic therapy.

**THIENOPYRIDINES**

Thienopyridines act by covalently binding to a cysteine residue of the P2Y12 platelet receptor (Figure 1). Con-
subsequently, platelets are affected for the remainder of their life span (7-10 days). Ticlopidine hydrochloride has been superseded by clopidogrel because clopidogrel has a faster onset of action and fewer adverse effects. The role of clopidogrel in relation to PCI has now been defined. The CURE study was the first major trial that demonstrated the benefit of adding clopidogrel to aspirin (additional 10% relative risk reduction) rather than using aspirin alone in patients with non-ST-segment elevation ACS or unstable angina. Patients who are resistant to aspirin (up to 10%) have higher rates of cardiovascular events. It is these patients who benefit most from combination therapy.

Clopidogrel use must be continued postinsertion of BMS for at least 4 weeks. Among patients receiving with an ACS, both the PCI-CURE and CREDO trials support long-term therapy post-PCI with BMS for 1 year. In the era of DES implantation, the current Food and Drug Administration recommendation is also to continue taking both antiplatelet agents for at least 1 year. Discontinuation prior to completing 1 year of therapy is considered premature withdrawal. The CHARISMA trial, which examined lower-risk patients who had not had a cardiovascular event or undergone PCI, showed no benefit of clopidogrel use in addition to aspirin in the context of primary prevention.

Gp IIb/IIIa INHIBITORS

The Gp IIb/IIIa inhibitors form the third major class of antiplatelet agents. The Gp IIb/IIIa receptors are present on resting platelets and undergo a conformational change on activation. They link to fibrinogen to form bridges between activated platelets (Figure 1), leading to the formation of platelet thrombi. Direct inhibitors of the Gp IIb/IIIa receptor have been tested in patients admitted with an ACS, patients receiving thrombolytic therapy for acute myocardial infarction, and patients undergoing PCI. Aspirin and heparin have always been administered in addition to Gp IIb/IIIa inhibitors in these settings.

There are 2 categories of Gp IIb/IIIa inhibitors. The first (eg, tirofiban hydrochloride and epifibatide) are competitive inhibitors of the Gp IIb/IIIa receptor, with a short half-life of up to 2 hours. The second group (eg, abciximab) are monoclonal antibodies directed against the Gp IIb/IIIa receptor. Abciximab, a chimeric (human/murine) IgG Fab fragment, produces almost irreversible inhibition. It takes more than 12 hours after stopping an infusion for the relative occupancy of the Gp IIb/IIIa receptors to decrease by 50%.

Five major randomized trials have demonstrated the efficacy of Gp IIb/IIIa inhibitors in the setting of PCI and ACS and they are increasingly used as an adjunct for the prevention of cardiac ischemic complications. Table 2 summarizes the characteristics of the main antiplatelet agents.

DUAL ANTIPLATELET/ TRIPLE ANTIPLATELET THERAPY

The current European and American guidelines recommend dual antiplatelet therapy (aspirin plus clopidogrel) for all patients who present with non-ST-segment elevation ACS. High-risk patients (with recurrent ischemia, ST-segment depression, elevated troponin levels, and diabetes mellitus) may also in addition receive a Gp IIb/IIIa receptor inhibitor.

BLEEDING AND ANTIPLATELET THERAPIES

Antiplatelet drugs predispose to bleeding. Coadministration of different antiplatelet therapies with different modes of action increases the risk of bleeding. The most common site of spontaneous bleeding in patients treated with clopidogrel or aspirin is the gastrointestinal tract. Bleeding is also common at arterial puncture sites in patients un-

---

**Figure 1.** Mode of action of the 3 main types of antiplatelet agents (thienopyridines [eg, clopidogrel], aspirin, and glycoprotein [Gp] IIb/IIIa inhibitors) in relation to inhibition of platelet function. ADP indicates adenosine triphosphate.

**Table 2. Characteristics of the Main Antiplatelet Agents**

<table>
<thead>
<tr>
<th>Antiplatelet Agent</th>
<th>Mode of Action</th>
<th>Onset of Action</th>
<th>Disappearance of Effect After Discontinuation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin</td>
<td>Irreversible inhibition of COX-1</td>
<td>Rapid if 160-mg dose</td>
<td>Effects last for lifetime of platelet (ie, 10 d)</td>
</tr>
<tr>
<td>Thienopyridines (eg, clopidogrel bisulfate)</td>
<td>Irreversible inhibition of cysteine residue of the P2Y12 platelet receptor</td>
<td>Rapid if suitable loading dose</td>
<td>Effects last for lifetime of platelet (ie, 10 d)</td>
</tr>
<tr>
<td>Gp IIb/IIIa inhibitors (eg, abciximab)</td>
<td>Strong inhibition of Gp IIb/IIIa receptor</td>
<td>Rapid</td>
<td>At least 12 h</td>
</tr>
<tr>
<td>Gp IIb/IIIa inhibitors (eg, epifibatide)</td>
<td>Competitive inhibition of Gp IIb/IIIa receptor</td>
<td>Rapid</td>
<td>A few hours</td>
</tr>
</tbody>
</table>

Abbreviations: COX-1, cyclooxygenase 1; Gp, glycoprotein.

(a) Reproduced with permission from the Canadian Journal of Anaesthesia.
ciated with the highest mortality.4,33,52 whereas intracerebral bleeding is uncommon but is asso-
ceritoneal bleeding is not uncommon with clopidogrel
in reference to its propensity to cause bleeding.51 Retro-
pidogrel has been referred to as the "surgeon's headache"
etate,65,66 and recombinant factor VIIa.67 It is unclear whether
disks of adverse clinical outcomes, including myocar-
duction of bleeding. They found the absolute increase in ma-
ations.59 Other treatments include administration of anti-fi-
of clopidogrel may be reversed with platelet transfu-
sary artery bypass graft, Akowuah et al64 found that con-
ishing secondary to antiplatelet therapy was independently pre-
creasing the relative risk of bleeding by up to 50%. Bleed-
trol was approximately 1%. Adding clopidogrel to aspirin
of bleeding in patients taking antiplatelet drugs. The gen-
some guidelines concerning treatment of bleeding in patients taking antiplatelet drugs. The gen-
ial principles of management of major bleeding also ap-
"surgeon's headache" in reference to its propensity to cause bleeding.52 Retro-
peritoneal bleeding is not uncommon but is associated with the highest mortality.4,33,52

The definition of bleeding differs greatly between
randomized trials that looked at antiplatelet therapies.53-55
Eikelboom and Hirsh56 summarized the incidence of ma-
jor bleeding in randomized trials of clopidogrel or clopi-
dogrel-containing dual antiplatelet therapy based on the
International Society on Thrombosis and Haemostasis57 de-
inition of bleeding. They found the absolute increase in ma-
jor bleeding with clopidogrel compared with placebo or con-
trol was approximately 1%. Adding clopidogrel to aspirin
increased the relative risk of bleeding by up to 50%. Bleed-
ing secondary to antiplatelet therapy was independently pre-
dictive of adverse clinical outcomes, including myocardial
infarction, stroke, and death.57,58

There are no specific guidelines concerning treatment of bleeding in patients taking antiplatelet drugs. The gen-
eral principles of management of major bleeding also ap-
apply to patients who bleed during clopidogrel, aspirin, or
abcinimab treatment (Figure 2). The antiplatelet effect of clopidogrel may be reversed with platelet transfu-
sions.56 Other treatments include administration of anti-fi-
brinolytic agents, such as aprotinin,60-64 desmopressin ac-
etate,57,66 and recombinant factor VIIa.67 It is unclear whether
these agents should be given prophylactically during ur-
gent surgery or only be administered when bleeding arises.
In a randomized trial of patients undergoing urgent coro-
nary artery bypass graft, Akowuah et al59 found that con-
tinuing aspirin and clopidogrel therapy with intraopera-
tive aprotinin administration was associated with reduced
postoperative blood loss and transfusion requirements com-
pared with stopping the antiplatelet treatment 5 days pre-
operatively but without giving intraoperative aprotinin.

PREMATURE WITHDRAWAL
OF ANTIPLATELET AGENTS

Oral antiplatelet agent compliance and premature inter-
ruption are of great concern to cardiologists; however,
there is little evidence to guide management in the peri-
operative period. Premature or inappropriate discon-
tinuation of antiplatelet therapy can have serious and
sometimes fatal outcomes.56 Collet et al60 found that oral
antiplatelet withdrawal was an independent risk factor
for death among 1358 consecutive patients admitted with
an ACS. A recent meta-analysis by Burger et al70 found
that single oral antiplatelet interruption may account for
10% of all vascular events whatever the arterial bed.

Interruption of oral antiplatelet therapy within the first
month following BMS insertion has been reported to be
associated with death rates of 25% to 50%.31 In patients
who have had a DES inserted, 8 studies have reported
premature interruption of oral antiplatelet therapy as one
of the highest risk factors for delayed stent thrombosis.
72-75 Daemen et al80 have recently suggested that late
stent thrombosis is also encountered, with no evidence
of diminution up to 3 years postinsertion of a DES.

Withdrawal of antiplatelet agents may induce a re-
bound or prothrombotic effect.76,81 In perioperative pa-
tients, this added risk as well as the underlying risk of
thromboembolism associated with surgery could be re-
sponsible for the high rates of thrombosis seen in pa-
tients who stop taking antiplatelet agents before major
surgical procedures, particularly after PCI. Recent Ameri-
can guidelines identify the risk of stent thrombosis from
premature antiplatelet drug discontinuation in patients
receiving DES at up to 29% with resultant risk of acute
myocardial infarction or death.82

SUBSTITUTES TO ORAL ANTIPLATELET AGENTS

There are no clinically useful alternatives to oral anti-
platelet agents whereby a drug with a shorter half-life
could be substituted prior to surgery.83,84 There is also
no literature to support the use of therapeutic heparin
as an alternative.71 Therapeutic doses of heparin given
preoperatively in patients undergoing cardiac surgery have
been found to significantly increase the rate of bleeding
and need for reexploration.85

ASPIRIN IN THE PERIOPERATIVE PERIOD

Most surgeons advise patients to stop taking aspirin at
least 7 to 10 days preoperatively. The French Society of
Anesthesiology and Intensive Care in 2001 questioned
this policy because of a reported increased incidence of
myocardial infarction86 and recommended that aspirin
use should not be stopped in the perioperative period un-
less the risk of hemorrhagic complications related to a
specific procedure appeared to be greater than the in-
crease in thrombotic/cardiovascular risk from withhold-
Table 3. Bleeding Risk Associated With Different Surgical Procedures With Regard to Antiplatelet Therapies87,a

<table>
<thead>
<tr>
<th>Type of Surgery</th>
<th>Drug Therapy</th>
<th>Situation</th>
<th>Hemorrhagic Risk</th>
<th>Level of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac surgery</td>
<td>Aspirin and NSAIDS</td>
<td>Preoperative</td>
<td>Modest increase in risk with few changes in transfusion rates</td>
<td>2-4</td>
</tr>
<tr>
<td></td>
<td>Thienopyridines</td>
<td></td>
<td>Possible increase in risk and exposure to transfusion</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Abciximab (plus aspirin)</td>
<td></td>
<td>Possible increase in risk and exposure to transfusion</td>
<td>3</td>
</tr>
<tr>
<td>Carotid artery surgery</td>
<td>Aspirin</td>
<td>Preoperative</td>
<td>No increased risk of cervical hematoma or intracranial bleeding</td>
<td>3</td>
</tr>
<tr>
<td>Transurethral prostatic section</td>
<td>Ticlopidine hydrochloride</td>
<td>Preoperative or postoperative</td>
<td>Increased risk and transfusion requirements</td>
<td>2</td>
</tr>
<tr>
<td>Gastrointestinal and general surgery</td>
<td>Aspirin and other NSAIDS</td>
<td>Preoperative</td>
<td>Contradictory findings</td>
<td>2-3</td>
</tr>
<tr>
<td></td>
<td>NSAIDS if patient is &lt;75 y</td>
<td>Postoperative by &lt;5 d</td>
<td>No increased risk or revision procedures for hemostasis</td>
<td>3</td>
</tr>
<tr>
<td>General surgery</td>
<td>Thienopyridines</td>
<td>Preoperative</td>
<td>High increase in risk</td>
<td>3-4</td>
</tr>
<tr>
<td>Intracranial surgery</td>
<td>All platelet function inhibition</td>
<td>Preoperative</td>
<td>Increased risk</td>
<td>3-4</td>
</tr>
</tbody>
</table>

Abbreviation: NSAID, nonsteroidal anti-inflammatory drug.

*a Reproduced with permission from the Canadian Journal of Anaesthesia.39

Because clopidogrel is seen as a more powerful antiplatelet agent than aspirin, most surgeons advise discontinuation prior to surgery. The timing of surgery is often dictated by the clinical circumstances in which clopidogrel has been prescribed. Clopidogrel therapy is advised for at least 4 weeks after placement of a BMS. If early surgery is undertaken with premature discontinuation of clopidogrel, the incidence of thrombotic complications and/or hemorrhagic events is extremely high.3031 As a result, elective surgery should be postponed for a period of 1 to 3 months following placement of a BMS.32

A recent Science Advisory from the American Heart Association, American College of Cardiology, and the American College of Surgeons82 emphasizes the importance of 12 months of dual antiplatelet therapy postinsertion of DES because of the risk of late stent stenosis due to delayed endothelialization. Elective procedures for which there is significant risk of perioperative or postoperative bleeding should be postponed until patients have completed an appropriate course of thienopyridine therapy. Howard-Alpe et al88 and Brilakis et al93 have highlighted the increased risk of stent thrombosis after noncardiac surgery post–DES insertion. This risk is increased if surgery is performed early after stenting and particularly if dual antiplatelet therapy is discontinued.

Collet and Montalescot,75 based on guidelines from the French Society of Anesthesiology and Intensive Care, have suggested an algorithm for patients receiving dual antiplatelet therapy after insertion of a DES who require surgery. This involves the surgeon and anesthesiologist assessing the bleeding risk, the cardiologist evaluating the risk of stent thrombosis, and all 3 devising an individual management plan. For example, if there is a major risk of both stent thrombosis and bleeding, surgery should be postponed for at least 6 to 12 months post-DES. If this is not possible, aspirin use should be continued and clopidogrel therapy stopped 5 days before surgery. If the bleeding risk is small and there is a major risk of stent thrombosis, then antiplatelet agents should be continued in the perioperative period.

Full recovery of platelet function requires complete replacement of exposed platelets. However, hemostatic competence does not require 100% of all circulating platelets to be functioning normally. The CURE trial33 found that clopidogrel therapy could be discontinued at least 5 days prior to coronary artery bypass graft with no increased bleeding complications. Hence, for the majority of cases, stopping clopidogrel therapy at least 5 days preoperatively will allow adequate hemostatic function prior to most surgical procedures.34

Gp IIb/IIIa INHIBITORS IN THE PERIOPERATIVE PERIOD

The combined results of the EPILOG and EPISTENT trials showed no significant increase in transfusion rates and major blood loss in patients treated with the Gp IIb/IIIa

©2009 American Medical Association. All rights reserved.

Downloaded From: by a Non-Human Traffic (NHT) User on 11/02/2018
inhibitor abciximab compared with placebo. However, the numbers of patients were small and those undergoing coronary artery bypass graft were operated on more than 12 hours after the administration of abciximab. Gammie et al showed that if abciximab was given within 12 hours of surgery, the rate of transfusion and hemorrhagic risk increased. With regard to the other Gp IIb/IIIa inhibitors (eg, epifibatide and tirofiban), their half-lives are shorter than abciximab; hence, stopping the infusion of the drug just before surgery will allow the drug effect to disappear when the surgery is finished.86,87 Until further studies are performed, the recommendations for patients treated with Gp IIb/IIIa inhibitors undergoing cardiac surgery should also apply to patients undergoing noncardiac surgery.

Surgeons are increasingly confronted by patients prescribed antiplatelet drugs.88 There is a delicate balance between ischemic risk from stopping use of these drugs and bleeding risk from continuing use.87 No randomized data exist in noncardiac surgery patients.89 The ischemic risk needs to be evaluated by a cardiologist and consensus reached as to the appropriate timing of surgery and when or if the antiplatelet medication should be stopped.71 There is little evidence-based guidance on restarting therapy; however, it would appear prudent to limit the interruption of antiplatelet therapy to as short a time as possible.

Communication with the cardiologist in the perioperative period is important in evaluating the risk associated with stopping the antiplatelet drug therapy but also in influencing the type of stent inserted into a patient for a particular surgical procedure.90,91 Insertion of a BMS that requires 4 weeks’ minimum antiplatelet treatment may stabilize the patient from a cardiac viewpoint and allow surgery to proceed within a reasonable time frame.

Premature withdrawal of antiplatelet medications must be understood as being a significant cause of morbidity and mortality.68-70 A perceived risk of bleeding events often leads to antiplatelet medications being stopped, but in many cases, the interruption is unjustified. Management of a patient who is bleeding while taking antiplatelet agents, such as clopidogrel, depends on the site and extent of bleeding. Multidisciplinary consultation should be considered with regard to discontinuation of antiplatelet agents, platelet transfusion, and the use of other agents, such as desmopressin acetate, recombinant factor VIIa, and aprotinin.

Elective surgery after coronary stenting should be deferred until use of antiplatelet agents can be safely stopped. The literature supports the view that emergency surgery soon after coronary stenting is associated with adverse outcomes with increased rates of stent thrombosis. If emergency surgery is necessary, the actions of antiplatelet agents, such as clopidogrel, can be reversed with platelet transfusions. Close liaison between surgery and cardiology is essential to minimize both the adverse cardiac risk and surgical risk in this group of patients.


The recent surge in the development and use of antiplatelet agents has underscored their central role in the management of vascular disease. As the number of vascular interventional procedures continues to increase, it is anticipated that more research will be done to further refine antiplatelet agents and discover new medications as well as find new uses for them. The information in this article is especially useful to surgeons as they are most likely to encounter a patient who is taking antiplatelet agents and is in need of an urgent or emergent surgical procedure. But, as practice boundaries continue to blur, surgeons as well as our colleagues in radiology, neurology, neurosurgery, orthopedics, emergency medicine, and other specialties will continue to prescribe antiplatelet medications and/or take care of patients whose medication regimen includes them. To that end, O’Riordan and colleagues have opened a door for surgeons to lead the way on enhancing patient safety relative to the use of these medications. To start, this article allows essential information about these medica-

tions to be at the fingertips of those specialists using them. That information provides a common language so that care can be delivered in a safe and efficient manner. Incorporating such essential information into a protocol is a key step toward placing patient safety at the forefront. Best practices and practice guidelines are already an integral part of medical and surgical practice and trends are showing improved care with this approach. We can no longer deliver the best care to patients by operating in silos. A central repository of information can be the beginning of providing efficient and safe patient care in a multidisciplinary environment. This should not be an opportunity missed to improve patient care and safety.

Grace S. Rozycki, MD, MBA

Correspondence: Dr Rozycki, Department of Surgery, Emory University School of Medicine, 69 Jesse Hill Dr SE, Ste 302, Atlanta, GA 30303 (grozyck@emory.edu).

Financial Disclosure: None reported.